Published in J Clin Oncol on June 10, 2008
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol (2011) 1.98
Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res (2010) 1.96
The miR-106b-25 cluster targets Smad7, activates TGF-β signaling, and induces EMT and tumor initiating cell characteristics downstream of Six1 in human breast cancer. Oncogene (2012) 1.95
Emerging role of Notch in stem cells and cancer. Cancer Lett (2008) 1.88
Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res (2010) 1.84
Molecular mechanisms of metastasis in breast cancer--clinical applications. Nat Rev Clin Oncol (2010) 1.83
High aldehyde dehydrogenase activity: a novel functional marker of murine prostate stem/progenitor cells. Stem Cells (2009) 1.67
An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer (2011) 1.62
The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol (2012) 1.53
Tissue-based identification of stem cells and epithelial-to-mesenchymal transition in breast cancer. Hum Pathol (2013) 1.50
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression. Urol Oncol (2010) 1.49
Migration rules: tumours are conglomerates of self-metastases. Br J Cancer (2009) 1.48
Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila) (2012) 1.44
Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat (2008) 1.41
Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33
Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst (2009) 1.31
Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther (2013) 1.23
Human hepatic cancer stem cells are characterized by common stemness traits and diverse oncogenic pathways. Hepatology (2011) 1.22
Wnt pathway activity in breast cancer sub-types and stem-like cells. PLoS One (2013) 1.21
Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res (2010) 1.21
Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol (2012) 1.20
The Warburg effect version 2.0: metabolic reprogramming of cancer stem cells. Cell Cycle (2013) 1.20
Antibodies targeting cancer stem cells: a new paradigm in immunotherapy? MAbs (2010) 1.20
Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol (2011) 1.18
Epithelial-to-mesenchymal transition (EMT) confers primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 1.18
Hedgehog signalling in breast cancer. Carcinogenesis (2009) 1.18
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer (2012) 1.18
The role of miR-206 in the epidermal growth factor (EGF) induced repression of estrogen receptor-alpha (ERalpha) signaling and a luminal phenotype in MCF-7 breast cancer cells. Mol Endocrinol (2009) 1.17
The role of breast cancer stem cells in metastasis and therapeutic implications. Am J Pathol (2011) 1.16
Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications. J Hepatol (2010) 1.16
Estrogen promotes stemness and invasiveness of ER-positive breast cancer cells through Gli1 activation. Mol Cancer (2014) 1.13
The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2013) 1.12
Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem (2011) 1.10
Preinvasive breast cancer. Annu Rev Pathol (2010) 1.08
Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway. Cell Cycle (2013) 1.08
Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta (2012) 1.08
Breast cancer in young women. Nat Rev Clin Oncol (2012) 1.07
Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol (2013) 1.05
A polymorphic variant in human MDM4 associates with accelerated age of onset of estrogen receptor negative breast cancer. Carcinogenesis (2009) 1.03
Combining hedgehog signaling inhibition with focal irradiation on reduction of pancreatic cancer metastasis. Mol Cancer Ther (2013) 1.02
A think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis. J Natl Cancer Inst (2014) 1.02
Regenerative therapy after cancer: what are the risks? Tissue Eng Part B Rev (2010) 1.01
Cancer stem-like cells enriched in Panc-1 spheres possess increased migration ability and resistance to gemcitabine. Int J Mol Sci (2011) 1.00
Endothelial cell-secreted EGF induces epithelial to mesenchymal transition and endows head and neck cancer cells with stem-like phenotype. Cancer Res (2014) 0.96
Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle (2012) 0.95
Cancer stem cell marker Bmi-1 expression is associated with basal-like phenotype and poor survival in breast cancer. World J Surg (2012) 0.94
Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells (2014) 0.93
Permanently blocked stem cells derived from breast cancer cell lines. Stem Cells (2010) 0.93
Down-regulation of the fetal stem cell factor SOX17 by H33342: a mechanism responsible for differential gene expression in breast cancer side population cells. J Biol Chem (2009) 0.93
Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat (2012) 0.93
Delineation of breast cancer cell hierarchy identifies the subset responsible for dormancy. Sci Rep (2012) 0.92
The role of cancer stem cells in breast cancer initiation and progression: potential cancer stem cell-directed therapies. Oncologist (2012) 0.92
Functional and genetic deconstruction of the cellular origin in liver cancer. Nat Rev Cancer (2015) 0.92
An imbalance in progenitor cell populations reflects tumour progression in breast cancer primary culture models. J Exp Clin Cancer Res (2011) 0.91
Doxorubicin-enriched, ALDH(br) mouse breast cancer stem cells are treatable to oncolytic herpes simplex virus type 1. BMC Cancer (2012) 0.90
Challenges in the development of future treatments for breast cancer stem cells. Breast Cancer (Dove Med Press) (2010) 0.89
Response of estrogen receptor-positive breast cancer tumorspheres to antiestrogen treatments. PLoS One (2011) 0.89
The Role of Cancer Stem Cells in the Organ Tropism of Breast Cancer Metastasis: A Mechanistic Balance between the "Seed" and the "Soil"? Int J Breast Cancer (2011) 0.89
Molecular marks for epigenetic identification of developmental and cancer stem cells. Clin Epigenetics (2010) 0.89
Preferential antitumor effect of the Src inhibitor dasatinib associated with a decreased proportion of aldehyde dehydrogenase 1-positive cells in breast cancer cells of the basal B subtype. BMC Cancer (2010) 0.89
Mesenchymal Stem Cell-Mediated Effects of Tumor Support or Suppression. Int J Mol Sci (2015) 0.89
Breast cancer biology: the multifaceted roles of mesenchymal stem cells. J Oncol (2008) 0.89
Defining a role for the homeoprotein Six1 in EMT and mammary tumorigenesis. J Clin Invest (2009) 0.88
Distinct prognostic values and potential drug targets of ALDH1 isoenzymes in non-small-cell lung cancer. Drug Des Devel Ther (2015) 0.87
Differential expression of HIF-1α in CD44+CD24-/low breast ductal carcinomas. Diagn Pathol (2011) 0.87
Genetic and epigenetic analysis of putative breast cancer stem cell models. BMC Cancer (2013) 0.87
Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer. Int J Mol Med (2015) 0.86
The biology of incipient, pre-invasive or intraepithelial neoplasia. Cancer Biomark (2010) 0.86
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity. Breast Cancer Res Treat (2011) 0.85
Defects in innate immunity render breast cancer initiating cells permissive to oncolytic adenovirus. PLoS One (2010) 0.85
Harnessing the immune system for the treatment of breast cancer. J Zhejiang Univ Sci B (2014) 0.85
Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24. Int J Cancer (2013) 0.85
Expression of osteoprotegerin, receptor activator of nuclear factor kappa-B ligand, tumor necrosis factor-related apoptosis-inducing ligand, stromal cell-derived factor-1 and their receptors in epithelial metastatic breast cancer cell lines. Cancer Cell Int (2012) 0.84
Downregulation of the transcription factor, FoxD3, is associated with lymph node metastases in invasive ductal carcinomas of the breast. Int J Clin Exp Pathol (2014) 0.84
Molecular profiling and computational network analysis of TAZ-mediated mammary tumorigenesis identifies actionable therapeutic targets. Oncotarget (2014) 0.83
Mesenchymal and stem-like cell properties targeted in suppression of chronically-induced breast cell carcinogenesis. Cancer Lett (2013) 0.82
The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol (2008) 0.82
Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. Br J Cancer (2016) 0.81
PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencing. PLoS One (2014) 0.81
Leptin as a mediator of tumor-stromal interactions promotes breast cancer stem cell activity. Oncotarget (2016) 0.81
Androgen receptor and prostate cancer stem cells: biological mechanisms and clinical implications. Endocr Relat Cancer (2015) 0.81
Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget (2015) 0.81
Can CD44+/CD24- Tumor Cells Be Used to Determine the Extent of Breast Cancer Invasion Following Neoadjuvant Chemotherapy? J Breast Cancer (2011) 0.81
Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner. BMC Cancer (2015) 0.80
Sox4 Expression Confers Bladder Cancer Stem Cell Properties and Predicts for Poor Patient Outcome. Int J Biol Sci (2015) 0.80
Transcriptional shift identifies a set of genes driving breast cancer chemoresistance. PLoS One (2013) 0.80
Radio-photothermal therapy mediated by a single compartment nanoplatform depletes tumor initiating cells and reduces lung metastasis in the orthotopic 4T1 breast tumor model. Nanoscale (2015) 0.80
Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget (2015) 0.80
Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. Cell Cycle (2015) 0.80
Norcantharidin, derivative of cantharidin, for cancer stem cells. Evid Based Complement Alternat Med (2013) 0.80
Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib. PLoS One (2014) 0.80
Faith, heresy and the cancer stem cell hypothesis. Future Oncol (2008) 0.79
Expression pattern of the apoptosis-stimulating protein of p53 family in p53+ human breast cancer cell lines. Cancer Cell Int (2013) 0.78
Resection of the primary tumor in stage IV breast cancer. World J Clin Oncol (2014) 0.78
Assessment of potential anti-cancer stem cell activity of marine algal compounds using an in vitro mammosphere assay. Cancer Cell Int (2013) 0.78
Koenimbin, a natural dietary compound of Murraya koenigii (L) Spreng: inhibition of MCF7 breast cancer cells and targeting of derived MCF7 breast cancer stem cells (CD44(+)/CD24(-/low)): an in vitro study. Drug Des Devel Ther (2015) 0.78
The emerging role of extracellular vesicle-derived miRNAs: implication in cancer progression and stem cell related diseases. J Clin Epigenet (2016) 0.78
Cancer Stem and Progenitor-Like Cells as Pharmacological Targets in Breast Cancer Treatment. Breast Cancer (Auckl) (2015) 0.78
An in vitro model for the study of human implantation. Am J Reprod Immunol (2011) 0.77
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med (1997) 32.63
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Generation of a functional mammary gland from a single stem cell. Nature (2006) 18.30
Purification and unique properties of mammary epithelial stem cells. Nature (2006) 15.98
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med (2007) 13.39
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst (2008) 11.93
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res (2005) 11.52
Cancer stem cells: an old idea--a paradigm shift. Cancer Res (2006) 9.76
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res (2006) 5.21
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
Growth patterns and the risk of breast cancer in women. N Engl J Med (2004) 4.78
An entire functional mammary gland may comprise the progeny from a single cell. Development (1998) 4.77
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A (2003) 4.69
Self-renewal and solid tumor stem cells. Oncogene (2004) 4.60
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene (2008) 4.53
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 4.47
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol (2004) 3.87
Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res (2005) 3.74
Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood (2005) 3.51
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Phenotypic characterization of murine primitive hematopoietic progenitor cells isolated on basis of aldehyde dehydrogenase activity. Stem Cells (2004) 2.80
The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. Clin Cancer Res (2002) 2.75
Deaths: preliminary data for 2004. Natl Vital Stat Rep (2006) 2.52
Deaths: leading causes for 2004. Natl Vital Stat Rep (2007) 2.20
Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene (2003) 2.16
Notch signaling in cancer. Curr Mol Med (2006) 2.14
Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia (2005) 2.13
Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene (2002) 1.96
BRCA1 functions as a breast stem cell regulator. J Med Genet (2004) 1.92
Notch4 and Wnt-1 proteins function to regulate branching morphogenesis of mammary epithelial cells in an opposing fashion. Dev Biol (1998) 1.90
Retracted Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer (2006) 1.89
Role of birthweight in the etiology of breast cancer. Int J Cancer (2006) 1.89
Pregnancy and the risk of breast cancer. Endocr Relat Cancer (2007) 1.72
Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev (2005) 1.65
Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia (2007) 1.62
Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer (2007) 1.58
The mammary gland "side population": a putative stem/progenitor cell marker? J Mammary Gland Biol Neoplasia (2005) 1.57
Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology (2006) 1.57
Mammography screening of women in their 40s: impact of changes in screening guidelines. Cancer (2008) 1.54
ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell (2007) 1.53
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol (2001) 1.42
Pten, tumorigenesis, and stem cell self-renewal. Cell (2006) 1.36
Correlation of umbilical cord blood hormones and growth factors with stem cell potential: implications for the prenatal origin of breast cancer hypothesis. Breast Cancer Res (2007) 1.35
Fetal origins of breast cancer. Trends Endocrinol Metab (2006) 1.35
The role of PTEN and its signalling pathways, including AKT, in breast cancer; an assessment of relationships with other prognostic factors and with outcome. J Pathol (2004) 1.21
Is there a role for Notch signalling in human breast cancer? Breast Cancer Res (2003) 1.21
Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. Breast Cancer Res Treat (2006) 1.21
Cancer stem cells and "stemness" genes in neuro-oncology. Neurobiol Dis (2006) 1.20
Acromegaly and cancer. Horm Res (2004) 1.14
Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res (2007) 1.12
Molecular basis of pregnancy-induced breast cancer protection. Eur J Cancer Prev (2006) 1.12
Growth retardation and neonatal lethality in mice with a homozygous deletion in the C-terminal domain of RNA polymerase II. Mol Gen Genet (1999) 1.08
Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification. Clin Cancer Res (2007) 1.04
The emerging picture of the mouse mammary stem cell. Stem Cell Rev (2007) 1.03
Impact of quercetin and EGCG on key elements of the Wnt pathway in human colon carcinoma cells. J Agric Food Chem (2006) 1.02
Morphogenic and tumorigenic potentials of the mammary growth hormone/growth hormone receptor system. Mol Cell Endocrinol (2002) 0.95
LRP5/6 in Wnt signaling and tumorigenesis. Future Oncol (2005) 0.95
Somatic stem cells and the origin of cancer. Clin Transl Oncol (2006) 0.93
The stem cell hypothesis in head and neck cancer. J Cell Biochem (2008) 0.92
Normal breast stem cells, malignant breast stem cells, and the perinatal origin of breast cancer. Stem Cell Rev (2006) 0.91
Insights into the cancer stem cell model of glioma tumorigenesis. Ann Acad Med Singapore (2007) 0.88
Stem cells and mammary cancer in mice. Stem Cell Rev (2005) 0.87
Stem cell plasticity and carcinogenesis. Neoplasma (2006) 0.81
Julius Cohnheim (1839-1884) experimental pathologist. JAMA (1968) 0.81
Effect of 1,25 dihydroxyvitamin D3 and retinoic acid on normal human pluripotent (CFU-mix), erythroid (BFU-E), and myeloid (CFU-C) progenitor cell growth and differentiation patterns. Exp Hematol (1986) 0.81
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev (2003) 20.77
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res (2009) 7.98
Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res (2006) 7.91
Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res (2009) 6.43
Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res (2004) 5.60
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
Stem cells in normal breast development and breast cancer. Cell Prolif (2003) 4.47
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res (2009) 4.47
CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest (2010) 4.22
Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol (2009) 3.67
Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci U S A (2012) 3.21
Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res (2011) 3.18
Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab (2004) 3.10
Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res (2005) 3.05
Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck (2010) 2.76
Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest (2011) 2.62
Targeting breast cancer stem cells. J Clin Oncol (2010) 2.53
Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival. Cancer Res (2011) 2.50
Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell (2012) 2.34
HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res (2013) 2.27
Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia (2005) 2.13
Cancer stem cells: a step toward the cure. J Clin Oncol (2008) 2.08
Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells. Int J Cancer (2011) 2.05
Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. Cancer Res (2009) 2.04
Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res (2010) 1.96
Sensitive capture of circulating tumour cells by functionalized graphene oxide nanosheets. Nat Nanotechnol (2013) 1.92
Regulation of cancer stem cells by cytokine networks: attacking cancer's inflammatory roots. Clin Cancer Res (2011) 1.91
Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res (2010) 1.88
Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res (2006) 1.84
Circulating tumor cells: not all detected cells are bad and not all bad cells are detected. J Clin Oncol (2011) 1.79
Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res Treat (2009) 1.77
Cancer stem cells in breast: current opinion and future challenges. Pathobiology (2008) 1.77
Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs (2007) 1.76
Targeting breast cancer stem cells. Mol Oncol (2010) 1.72
Stem cells in mammary development and carcinogenesis: implications for prevention and treatment. Stem Cell Rev (2005) 1.65
HER-2, notch, and breast cancer stem cells: targeting an axis of evil. Clin Cancer Res (2009) 1.59
Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle (2009) 1.56
HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res (2012) 1.47
Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res (2013) 1.43
Point: cancer stem cells--the evidence accumulates. Clin Chem (2012) 1.43
Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res (2012) 1.39
An embryonic stem cell-like signature identifies poorly differentiated lung adenocarcinoma but not squamous cell carcinoma. Clin Cancer Res (2009) 1.38
MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet (2012) 1.38
Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia (2012) 1.25
Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res (2013) 1.20
Ablation of breast cancer stem cells with radiation. Transl Oncol (2011) 1.15
HER2 and breast cancer stem cells: more than meets the eye. Cancer Res (2013) 1.14
Mammary stem cell number as a determinate of breast cancer risk. Breast Cancer Res (2007) 1.12
Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med (2008) 1.12
Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem (2011) 1.10
Distinct FAK activities determine progenitor and mammary stem cell characteristics. Cancer Res (2013) 1.04
Cancer stem cells: implications for cancer treatment and prevention. Cancer J (2007) 1.04
Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res (2008) 1.04
Stem cells in normal development and cancer. Prog Mol Biol Transl Sci (2010) 0.98
Getting to the root of BRCA1-deficient breast cancer. Cell Stem Cell (2009) 0.95
Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol (2013) 0.95
Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells (2014) 0.93
Cancer stem cells: nature versus nurture. Nat Cell Biol (2010) 0.92
New organizational and funds flow models for an academic cancer center. Acad Med (2004) 0.91
Regulatory roles of miRNA in the human neural stem cell transformation to glioma stem cells. J Cell Biochem (2014) 0.91
Breast cancer stem cells: we've got them surrounded. Clin Cancer Res (2012) 0.90
Notch reporter activity in breast cancer cell lines identifies a subset of cells with stem cell activity. Mol Cancer Ther (2015) 0.89
Breast cancer stem cells-research opportunities utilizing mathematical modeling. Stem Cell Rev (2007) 0.88
A radial flow microfluidic device for ultra-high-throughput affinity-based isolation of circulating tumor cells. Small (2014) 0.88
Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle (2012) 0.86
[The cancer stem cell: the breast cancer driver]. Med Sci (Paris) (2007) 0.85
CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat (2015) 0.84
Inflammation and autophagy conspire to promote tumor growth. Cell Cycle (2011) 0.84
Breast cancer stem cells: current advances and clinical implications. Methods Mol Biol (2015) 0.83
Targeting cancer stem cells via dendritic-cell vaccination. Oncoimmunology (2012) 0.82
Identification of single chain antibodies to breast cancer stem cells using phage display. Biotechnol Prog (2009) 0.82
Stemming a tumor with a little miR. Nat Med (2011) 0.81
The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype. Endocr Relat Cancer (2013) 0.81
[Stem cells and epithelial cancers: the example of breast cancer]. Ann Pathol (2008) 0.78
Migratory gene expression signature predicts poor patient outcome: are cancer stem cells to blame? Breast Cancer Res (2012) 0.78
KRAS and cancer stem cells in APC-mutant colorectal cancer. J Natl Cancer Inst (2014) 0.77
Antiangiogenic agents: fueling cancer's hypoxic roots. Cell Cycle (2012) 0.77
Generation of a novel dendritic-cell vaccine using melanoma and squamous cancer stem cells. J Vis Exp (2014) 0.77
Development of 'synthetic lethal' strategies to target BRCA1-deficient breast cancer. Breast Cancer Res (2009) 0.76
Clinical trial design for testing the stem cell model for the prevention and treatment of cancer. Cancers (Basel) (2011) 0.75
Breast tumors: of mice and women. Breast Cancer Res (2010) 0.75
Single cell dual adherent-suspension co-culture micro-environment for studying tumor-stromal interactions with functionally selected cancer stem-like cells. Lab Chip (2016) 0.75
Tumor-initiating cells and treatment resistance: how goes the war? J Mammary Gland Biol Neoplasia (2009) 0.75